Saxon S A, Silverman M E
Am J Cardiol. 1985 Sep 1;56(7):461-4. doi: 10.1016/0002-9149(85)90886-0.
The effect of continuous infusion of intravenous nitroglycerin (NTG) on methemoglobin levels in 24 coronary care unit patients was studied. Fifteen patients were admitted with acute myocardial infarction, 5 patients with angina pectoris, 1 patient with congestive heart failure, 2 with chest pain of unknown origin and 1 with chest pain of musculoskeletal origin. Intravenous NTG therapy was initiated at a 5 micrograms/min dose and titrated at 5-micrograms increases until relief of symptoms or until the maximal dose tolerated by each patient. Successive methemoglobin levels were measured at baseline, at each 20 micrograms/min dose increase, at the maximal dose and immediately before weaning the patient from the maximal dose. Statistical analysis by the Student t test (paired samples, p less than 0.05) showed no significant difference between the mean methemoglobin levels at baseline and the mean methemoglobin levels drawn at 20, 40 and 60 micrograms, and before weaning from the maximal dose. No serious adverse effects associated with methemoglobinemia were encountered. It is concluded that intravenous NTG administration in a dose of 0.2 to 2.12 micrograms/min/kg body weight produces no significant methemoglobinemia.
研究了24例冠心病监护病房患者持续静脉输注硝酸甘油(NTG)对高铁血红蛋白水平的影响。15例患者因急性心肌梗死入院,5例因心绞痛入院,1例因充血性心力衰竭入院,2例因不明原因胸痛入院,1例因肌肉骨骼源性胸痛入院。静脉NTG治疗以5微克/分钟的剂量开始,并以每次增加5微克的速度滴定,直至症状缓解或达到每位患者耐受的最大剂量。在基线、每次剂量增加20微克/分钟时、最大剂量时以及在患者从最大剂量撤药前立即测量连续的高铁血红蛋白水平。采用学生t检验(配对样本,p<0.05)进行统计分析,结果显示基线时的平均高铁血红蛋白水平与剂量增加至20、40和60微克时以及撤药前的平均高铁血红蛋白水平之间无显著差异。未遇到与高铁血红蛋白血症相关的严重不良反应。结论是,以0.2至2.12微克/分钟/千克体重的剂量静脉给予NTG不会产生显著的高铁血红蛋白血症。